Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELEFIRST: Telotristat Ethyl + Lanreotide in siNET
NCT04065165Phase 3Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2020
- Primary completion
- Jul 2023
01
Overview
Phase 3, randomised, double-blind trial of telotristat ethyl in Carcinoid Syndrome (CS), sponsored by European Organisation for Research and Treatment of Cancer. Planned start Apr 2020; status: withdrawn.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT04065165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065165.